CSTL vs GH
CSTL: Castle Biosciences is a molecular diagnostics company offering gene expression profile tests to improve management of dermatologic and gastrointestinal cancers. GH: Guardant Health is a leader in precision oncology, utilizing advanced liquid biopsy technology to provide comprehensive genomic insights across the cancer care continuum.
Side-by-side fundamentals
| Metric | CSTL | GH | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $33.71 | $165.56 | |
| Market cap | $1.0B | $22.2B | |
| Net margin FY2025, SEC XBRL | -7.0% | -42.4% | CSTL higher |
| Operating margin FY2025, SEC XBRL | -12.4% | -44.5% | CSTL higher |
| ROE FY2025, SEC XBRL | -5.1% | n/a | |
| ROA FY2025, SEC XBRL | -4.2% | -20.7% | CSTL higher |
| Debt / equity as of 2026-09-03 | 0.02 | 16.78 | CSTL lower |
| Revenue growth (YoY) as of 2026-09-03 | +3.2% | +42.7% | GH higher |
| Revenue CAGR (3y) SEC XBRL | +35.9% | +29.8% | CSTL higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.82 | 1.23 | |
| 1-year return as of 2026-10-08 close | +42.9% | +153.5% | GH higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.